Drug Type Antibody drug conjugate (ADC) |
Synonyms BNT-3212, PM1300 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | China | 20 Aug 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 20 Aug 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 20 Aug 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 20 Aug 2025 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | - | 01 Aug 2025 | |
Neoplasms | Preclinical | China | 22 Mar 2024 |